These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. Vitale GD, deKemp RA, Ruddy TD, Williams K, Beanlands RS. J Nucl Med; 2001 Dec; 42(12):1730-6. PubMed ID: 11752067 [Abstract] [Full Text] [Related]
5. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, Mäki M, Ruotsalainen U, Härkönen R, Teräs M, Haaparanta M, Bergman J, Hartiala J, Wegelius U, Nuutila P. J Nucl Med; 1994 Jun; 35(6):989-98. PubMed ID: 8195886 [Abstract] [Full Text] [Related]
6. [Appropriate uptake period for myocardial PET imaging with 18F-FDG after oral glucose loading]. Brink I, Nitzsche EU, Mix M, Schindler T, Hentschel M, Högerle S, Moser E. Nuklearmedizin; 2003 Feb; 42(1):39-44. PubMed ID: 12601453 [Abstract] [Full Text] [Related]
9. Simplified PET quantitation of myocardial glucose utilization. Nakagawa K, Namba H, Iyo M, Fukushi K, Irie T, Yamanouchi M, Shikama N, Himi T, Yoshida K, Masuda Y. J Nucl Med; 1995 Nov; 36(11):2094-102. PubMed ID: 7472605 [Abstract] [Full Text] [Related]
10. Myocardial FDG PET studies with the fasting, oral glucose-loading or insulin clamp methods. Tamaki N, Yonekura Y, Konishi J. J Nucl Med; 1992 Jul; 33(7):1263, 1266-8. PubMed ID: 1613563 [No Abstract] [Full Text] [Related]
11. Effect of nicotinic acid on exogenous myocardial glucose utilization. Stone CK, Holden JE, Stanley W, Perlman SB. J Nucl Med; 1995 Jun; 36(6):996-1002. PubMed ID: 7769458 [Abstract] [Full Text] [Related]
12. Comparison of 1-(11)C-glucose and (18)F-FDG for quantifying myocardial glucose use with PET. Herrero P, Sharp TL, Dence C, Haraden BM, Gropler RJ. J Nucl Med; 2002 Nov; 43(11):1530-41. PubMed ID: 12411556 [Abstract] [Full Text] [Related]
13. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, Phelps ME. J Nucl Med; 1989 Mar; 30(3):359-66. PubMed ID: 2786939 [Abstract] [Full Text] [Related]
14. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH, Visser CA. Eur J Nucl Med; 1997 Jan; 24(1):35-41. PubMed ID: 9044874 [Abstract] [Full Text] [Related]
15. Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results. Schröder O, Hör G, Hertel A, Baum RP. Nucl Med Commun; 1998 Sep; 19(9):867-74. PubMed ID: 10581593 [Abstract] [Full Text] [Related]
18. Simple quantification of regional myocardial uptake of fluorine-18-deoxyglucose in the fasting condition. Tamaki N, Yonekura Y, Kawamoto M, Magata Y, Sasayama S, Takahashi N, Nohara R, Kambara H, Kawai C, Konishi J. J Nucl Med; 1991 Nov; 32(11):2152-7. PubMed ID: 1941154 [Abstract] [Full Text] [Related]